Abstract
The present study aimed to illustrate the association of the expression of ubiquitin-conjugating enzyme E2A (UBE2A) with the clinicopathological parameters and prognosis in hepatocellular carcinoma (HCC). The expression levels of UBE2A mRNA and protein in a total of 276 HCC tissues and six liver cell lines was detected by fluorescent quantitative polymerase chain reaction, western blotting and immunohistochemistry. Statistical analysis was also performed to assess the association of the expression of UBE2A with the clinicopathological parameters and prognosis by the GraphPad Prism and SPSS version 21.0 software. UBE2A mRNA and protein were highly expressed in HCC tissues compared with those in the adjacent normal tissue. Immunohistochemical analysis revealed that UBE2A protein was more strongly stained in the 276 paraffin-embedded HCC tissues as compared with the 63 adjacent normal tissue. Statistical analysis also demonstrated that UBE2A expression was significantly associated with histological differentiation, TNM stage and vascular invasion of HCC (P<0.05). Notably, HCC patients with a high expression of UBE2A had a shorter survival time as compared with those with a low expression of UBE2A. There results suggested that UBE2A may be involved in the pathogenesis of HCC and may serve as an important prognostic marker. Further exploration of the involvement of UBE2A in HCC development may provide novel therapeutic targets.
Highlights
Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐associated mortality worldwide and the fifth most common cancer type [1]
A recent study demonstrated that the hepatitis C virus NS3 protein enhanced HCC cell invasion by promoting protein phosphatase magnesium‐dependent 1A ubiquitination and degradation [18], which indicated degradation and ubiquitination of proteins were involed in SHEN et al: ubiquitin‐conjugating enzyme E2A (UBE2A) AND HCC PROGNOSIS
UBE2A mRNA expression was significantly increased in HCC tissues (9.55±8.84) compared with the adjacent normal tissue (5.74±2.25; P
Summary
Hepatocellular carcinoma (HCC) is the third leading cause of cancer‐associated mortality worldwide and the fifth most common cancer type [1]. Despite advances in the diagnosis [8] and treatment [9] of HCC, the prognosis of this disease remains poor [10]. There is an urgency to develop a novel biomarker for the prognosis of HCC. A recent study demonstrated that the hepatitis C virus NS3 protein enhanced HCC cell invasion by promoting protein phosphatase magnesium‐dependent 1A ubiquitination and degradation [18], which indicated degradation and ubiquitination of proteins were involed in SHEN et al: UBE2A AND HCC PROGNOSIS the deveopment of HCC. UBE2A is a member of a group of E2 enzymes [20] that are involved in DNA damage repair by catalyzing the ubiquitination of different target proteins [21]. The role and function of UBE2A in HCC remain unknown. The fold amplification for each gene was calculated using the 2‐ΔΔCq method [26]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
